UPDATE 2-U.S. FDA asks Sanofi, Regeneron to assess cholesterol drug's cognitive risks

March 7 (Reuters) - The U.S. Food and Drug Administration has asked Regeneron and Sanofi to assess potential neurocognitive side effects of their experimental cholesterol drug, Sanofi said in its annual report on Friday.